Talking Medicines targets messaging risk in pharma brand strategy

Tern plc

Pharma teams typically begin with a clear brand narrative built on scientific evidence. But as this narrative moves through marketing, compliance and external agencies, the original message can become diluted. When that happens, healthcare professionals may misinterpret or disengage from the brand. The result is weaker positioning, lower impact and reduced return on marketing investment.

Talking Medicines addresses this problem by offering real-time analytics that measure how healthcare professionals actually receive and interpret brand messages. Instead of waiting for post-campaign reports, teams can see early signals of what is working and adjust strategy before value is lost. This is especially relevant during launch phases, where the ability to course-correct quickly can have a material impact on performance.

Its DrugVoice platform captures unstructured HCP dialogue and turns it into structured insight. This data helps brand teams understand whether their messages are understood, aligned with clinical priorities and prompting the right actions. For leadership, it offers a way to verify that brand strategy is being delivered as intended.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Device Authority highlights security risks as AI begins controlling physical machines

Device Authority examines the security risks of AI-controlled machinery and the role of device identity, authentication and access controls...

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies....

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control...

Search